Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma. by Park, S.I. et al.
  
Serveur Académique Lausannois SERVAL serval.unil.ch 
Author Manuscript 
Faculty of Biology and Medicine Publication 
This paper has been peer-reviewed but dos not include the final publisher 
proof-corrections or journal pagination. 
Published in final edited form as:  
 
In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains 
an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article. 
 
Title: Pretargeted radioimmunotherapy using genetically engineered 
antibody-streptavidin fusion proteins for treatment of non-hodgkin 
lymphoma. 
Authors: Park SI, Shenoi J, Frayo SM, Hamlin DK, Lin Y, Wilbur DS, 
Stayton PS, Orgun N, Hylarides M, Buchegger F, Kenoyer AL, Axtman A, 
Gopal AK, Green DJ, Pagel JM, Press OW 
Journal: Clinical cancer research : an official journal of the American 
Association for Cancer Research 
Year: 2011 Dec 1 
Volume: 17 
Issue: 23 
Pages: 7373-82 
DOI: 10.1158/1078-0432.CCR-11-1204 
 
Pretargeted Radioimmunotherapy using Genetically Engineered
Antibody-Streptavidin Fusion Proteins for Treatment of Non-
Hodgkin Lymphoma
Steven I. Park1,#, Jaideep Shenoi2,3,#, Shani M. Frayo2, Donald K. Hamlin4, Yukang Lin2, D.
Scott Wilbur4, Patrick S. Stayton5, Nural Orgun2, Mark Hylarides2, Franz Buchegger6,
Aimee L. Kenoyer2, Amanda Axtman2, Ajay K. Gopal2,3, Damian J. Green2,3, John M.
Pagel2,3, and Oliver W. Press2,3
1 Department of Medicine, University of North Carolina, Chapel Hill, NC, USA 2 Clinical Research
Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 3 Department of Medicine,
University of Washington, Seattle, WA, USA 4 Department of Radiation Oncology, University of
Washington, Seattle, WA, USA 5 Department of Bioengineering, University of Washington,
Seattle, WA 6 University Hospital of Lausanne, CH-1011 Lausanne, Switzerland.
Abstract
Purpose—Pretargeted radioimmunotherapy (PRIT) using streptavidin (SAv)-biotin technology
can deliver higher therapeutic doses of radioactivity to tumors than conventional RIT. However,
“endogenous” biotin can interfere with the effectiveness of this approach by blocking binding of
radiolabeled biotin to SAv. We engineered a series of SAv FPs that down-modulate the affinity of
SAv for biotin, while retaining high avidity for divalent DOTA-bis-biotin to circumvent this
problem.
Experimental Design—The single-chain variable region gene of the murine 1F5 anti-CD20
antibody was fused to the wild-type (WT) SAv gene and to mutant SAv genes, Y43A-SAv and
S45A-SAv. FPs were expressed, purified and compared in studies using athymic mice bearing
Ramos lymphoma xenografts.
Results—Biodistribution studies demonstrated delivery of more radioactivity to tumors of mice
pretargeted with mutant SAv FPs followed by 111In-DOTA-bis-biotin (6.2 ± 1.7 % of the injected
dose per gram [%ID/gm] of tumor 24 hours after Y43A-SAv FP and 5.6 ± 2.2 %ID/g with S45A-
SAv FP) than in mice on normal diets pretargeted with WT-SAv FP (2.5 ± 1.6 %ID/g; p = 0.01).
These superior biodistributions translated into superior anti-tumor efficacy in mice treated with
mutant FPs and 90Y-DOTA-bis-biotin (tumor volumes after 11 days: 237 ± 66 mm3 with Y43A-
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SAv, 543 ± 320 mm3 with S45A-SAv, 1129 ± 322 mm3 with WT-SAv and 1435 ± 212 mm3 with
control FP [p < 0.0001]).
Conclusions—Genetically engineered mutant-SAv FPs and bis-biotin reagents provide an
attractive alternative to current SAv-biotin PRIT methods in settings where endogenous biotin
levels are high.
Keywords
radioimmunotherapy; CD20; lymphoma
INTRODUCTION
Despite advances in the management of lymphoma, fewer than 60% of patients with
aggressive non-Hodgkin lymphomas (NHL) and fewer than 5% of patients with indolent
lymphomas can be cured with conventional chemotherapy (1-3). The remaining patients
eventually relapse, and the disease becomes progressively more chemotherapy-resistant.
This does not preclude the therapeutic benefit of radiation therapy; however, since
lymphoma cells remain highly susceptible to even low-doses of radiation regardless of their
inherent resistance to chemotherapeutic drugs. For this reason, radioimmunotherapy (RIT)
has emerged as a promising treatment option for NHL. RIT has yielded excellent overall
response rates of 50% to 80%, with complete response rates of 20% to 40% in patients with
relapsed or refractory indolent lymphoma treated with iodine-131 (131I) tositumomab
(Bexxar, GlaxoSmithKline) or yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin, Spectrum)
(4-7). Nevertheless, most patients treated with conventional doses of RIT eventually relapse
even after favorable initial responses. Dose-escalation of RIT to myeloablative levels with
stem-cell support significantly reduces the risk of relapse by delivering potentially curative
radiation doses to tumor sites. However, this approach has been associated with significant
treatment-related morbidity and mortality (8-10).
One strategy for delivering higher, potentially curative, radiation doses to tumors involves a
multi-step “pretargeting” method. The major cause of dose limiting toxicities in
conventional RIT is due to the slow clearance of unbound radiolabeled antibodies (Ab) from
the circulation with resultant high levels of background radioactivity in normal tissues
(11-13). Pretargeted radioimmunotherapy (PRIT) dissociates the slow distribution phase of
the Ab molecule from administration of the therapeutic radionuclide. This approach permits
the tumor-reactive Ab to localize and accumulate at tumor sites without subjecting the rest
of the body to nonspecific irradiation from circulating radiolabeled Ab (14-17). After
maximal accumulation of Ab in the tumor, a small molecular weight radioactive moiety,
which has high affinity for the tumor-reactive Ab is administered. This second reagent
penetrates tumors rapidly due to its small size. Excess unbound molecules of the second
radioactive reagent are also rapidly cleared from the blood and excreted in the urine due to
their small size. To facilitate this process, a “clearing agent” (CA) may be injected before
the radiolabeled small molecule to enhance elimination of the unbound Ab from the
bloodstream thus preventing it from complexing with the radiolabeled small molecule in the
circulation.
Preclinical data have demonstrated that streptavidin (SAv)-biotin pretargeting strategies can
dramatically increase the tumor-to-normal organ ratio of delivered radioactivity by 10 to 100
fold (16-18). Pilot clinical trials have also demonstrated promising results in both solid
tumor and lymphoma models, though the outcomes were not as dramatic as those observed
in preclinical studies (19-22). Suboptimal responses observed in the pilot clinical trials may
be partially attributable to the presence of competing endogenous biotin in patient serum,
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derived from dietary sources. Biotin is present in blood and tissues at sufficient
concentrations to irreversibly block the biotin binding sites of SAv and may impair its
efficacy in pretargeting applications (21),(23). In preclinical studies, mice may be fed a
biotin-deficient diet for several days prior to the therapy to reduce the endogenous biotin
concentration in serum. In contrast, biotin-depletion in human clinical trials is more
problematic due to the ubiquitous presence of this vitamin in all common foods, patient non-
compliance, and concerns over complications attributable to biotin deficiency. Although the
serum concentration of biotin present in humans is somewhat lower than in mice,
endogenous biotin remains a significant concern, particularly because the liver acts as a
storage and release-reservoir for biotin (24). Strategies that avoid the blocking of the biotin-
binding sites of SAv by endogenous biotin may therefore offer therapeutic advantages. To
address this issue, Stayton and colleagues produced a large library of SAv variants by site-
directed mutagenesis directed at the SAv binding pocket (Table S1), covering a wide range
of Ka and Koff properties (25-26). Along with the engineering of SAv mutants, divalent bis-
biotin ligands were designed to effectively engage two adjacent biotin binding sites of SAv
mutants, thus overcoming the competitive binding by endogenous biotin (27-29). The lower
affinities and faster biotin off-rates of the SAv mutants allow exchange of pre-bound
endogenous biotin, while the dual binding of the bis-biotin ligand results in a striking avidity
effect and essentially irreversible capture of the modified divalent ligand (27, 30-32). In this
manuscript, we describe the synthesis and characterization of two SAv mutant fusion
proteins (FPs), S45A-SAv and Y43A-SAv. The FPs were selected based on previous kinetic
studies suggesting they were the most promising candidates that would allow exchange of
pre-bound monovalent endogenous biotin while retaining sufficiently high affinity to
efficiently capture radiolabeled divalent bis-biotin ligands (27, 29). We report here the blood
clearance of the mutant-SAv FPs using a standard monovalent biotin CA or a novel bivalent
biotin CA, specifically designed for this application. Finally, we compare the targeting,
biodistributions, and therapeutic efficacy of PRIT strategies utilizing either conventional
wild type (WT)-SAv and biotin or mutant-SAv and bis-biotin reagent combinations.
MATERIALS AND METHODS
Cell culture
The human Ramos Burkitt lymphoma cell line was obtained from the American Type
Culture Collection (ATCC). Cell lines were maintained in log phase growth in RPMI 1640
medium supplemented with 10% heat-inactivated fetal calf serum in a 5% CO2 incubator.
Cell viability exceeded 95% by trypan blue exclusion.
WT-SAv FP and mutant-SAv FPs
The development of the 1F5-WT-SAv FP has been previously described (33-35). Briefly,
the process involved fusion of the single-chain variable regions (scFv) of the murine anti-
CD20 1F5 Ab to the full length genomic SAv of Streptomyces avidinii wild type (WT) gene
to obtain the 1F5(scFv)4SAv fusion gene. This gene construct was modified by PCR-based
site-directed mutagenesis to produce mutant genes carrying either the S45A or the Y43A
mutations, with an SSGSGSA peptide linker between the SAv and the scFv genes in each
construct. The residue changes in fusion genes were determined by DNA sequencing
analysis, and the gene products were analyzed by mass spectroscopy, which indicated all
FPs differed only at the deliberately engineered positions without any extraneous mutations
(data not shown). E. coli XL1 Blue (Stratagene) transformants of the gene constructs, WT-
SAv, S45A-SAv, or Y43A-SAv, were grown in shaker flasks under control of an IPTG
inducible lac promoter for qualitative expression of the FPs. A 4 L fermentor (BioFlo 3000;
New Brunswick Scientific) was used for bulk production of FPs. The FPs were purified by
iminobiotin chromatography as described (18), except that the loading pH was raised from
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9.2 to 11 due to the reduced affinities of the mutant FPs for iminobiotin. (33-35). Aggregates
were reduced to ~3% by treatment with 20% DMSO. The eluted FPs were dialyzed against
phosphate buffered saline (PBS) at 4 °C overnight and concentrated to 2.0-2.3 mg/ml using
a YM30 membrane. The final FPs were filter-sterilized and stored in 5% sorbitol at -80 °C.
A negative control FP (CC49-WT-SAv) that recognizes the TAG 72 antigen expressed on
human adenocarcinomas, but not on lymphomas, was prepared similarly.
Pretargeting reagents
A synthetic, dendrimeric CA containing 16 N-acetylgalactosamine residues and a single
biotin residue per molecule (NAGB) was obtained from Aletheon Pharmaceuticals for use
with 1F5-WT-SAv FP, as described previously (35). A bis-biotin-trigalactose (BBTG) CA
containing two biotin moieties and three galactose residues (C127H218N19O51S6) was used
for the clearance of mutant-SAv FPs. The syntheses of BBTG CA and DOTA-bis-biotin
have been recently described (28).
Radiolabeling of biotin compounds
111In labeling of DOTA-biotin and DOTA-bis-biotin were conducted as published (28). 90Y
labeling for therapy was performed similarly, using 2 mg/mL DOTA-bis-biotin, 500mM
ammonium acetate pH 5.3 and 90Y heated for 30 minutes at 85°C. After cooling to room
temperature, 100 mM DTPA was added.
In vitro characterization
The FPs were analyzed by SDS-PAGE on 4-12% Tris-glycine gels (Invitrogen) under non-
reducing conditions. The gels were stained with 0.2% Coomassie blue solution and de-
stained in acetic acid-methanol solution. Size-exclusion high-performance liquid
chromatography (HPLC) analysis was performed on a Zorbax GF-250 column (9.4 × 250
mm, 4μm; Agilent) with 20 mM sodium phosphate/0.5 M sodium chloride/15% dimethyl
sulfoxide (DMSO; pH 6.8-7.0) as a mobile phase (1ml/min) and A280 as a detection
wavelength on a Dynamax system. Matrix-assisted laser desorption/ionization (MALDI)
mass spectrometry performed on a Voyager DE Pro MALDI time-of-flight mass
spectrometer (Applied Biosystems) was used to ascertain the molecular weight of the FPs.
The CD20 binding ability of the FPs was assessed using PE-biotin labeled FPs and Ramos
target cells. Cells (0.1 × 106 per sample) were incubated with 30 μl of 10 μg/ml 1F5
(positive control) Ab, HB8181 (non-binding isotype control) Ab, 1F5-Y43A-SAv FP, 1F5-
S45A-SAv FP, 1F5-WT-SAv FP, or CC49-WT-SAv FP (negative control) for 30 minutes at
4°C. Cells were washed and incubated with 30 μl 1:64 goat anti-mouse IgG (Fab specific)
FITC conjugate (Sigma-Aldrich) in PBS. Cells were washed and fluorescence intensity was
measured on FACS Canto I flow cytometer (BD). An in vitro cell binding assay was also
performed by incubating Ramos cells (1.0 × 106 per sample) with 25 μl of 20ug/ml 1F5-
Y43A-SAv, 1F5-S45A-SAv, 1F5-WT-SAv, or CC49-WT-SAv FPs in a 96 round bottom
ELISA plate at 4 °C for 60 minutes. Cells were then washed twice in 200 μl PBS. Next,
similar molar amounts of 90Y-DOTA–biotin (100 ng/ml) or 90Y-DOTA–bis-biotin (100 ng/
ml) were added to the cells and incubated at 4°C for 60 minutes. Cells were washed twice
with PBS. Cells were collected using cotton swabs and 90Y activity measured in a gamma
counter.
Blood clearance studies
Three groups of four athymic mice each were injected via the tail vein (i.v.) with 125I-1F5-
Y43A-SAv or 125I-1F5-S45A-SAv FPs (2.8 nmol) followed 24 hours later by i.v. injection
of 5.8 nmol of either NAGB or BBTG CA. Venous sampling was performed via the tail vein
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at serial time points up to 68 hours. 125I was counted on a gamma counter and the percent of
the injected dose per gram (%ID/g) of blood was calculated.
Mouse Xenograft Model
FoxN1Nu athymic female mice (6-8 weeks old) were obtained from Harlan Sprague-Dawley
and housed in the FHCRC animal facility after approval of the experimental protocol by the
Institutional Animal Care and Use Committee. Some groups of mice were switched to a
biotin-deficient diet (Purina Mills) 5-6 days prior to PRIT studies. Ramos cells (10 × 106)
were injected subcutaneously in the right flank 10 days prior to experiments to produce
lymphoma xenografts measuring 6 - 10 mm in diameter. Anti-asialoGM1 antiserum (30 μl,
WAKO) was injected 9 days and 6 days prior to FP injection to abrogate natural killer cell
activity and prevent spontaneous tumor regressions.
Biodistribution studies
Biodistribution experiments were performed using the “double label” method of Pressman
by trace-labeling the 1F5-SAv FPs with 125I and the biotin moiety with 111In to allow
independent assessment of tumor targeting of the FPs and the biotin ligands (36). Groups of
5 mice with similar-sized tumors were injected i.v. with 2.8 nmol (400 μg) of 1F5-WT-SAv,
1F5-Y43A-SAv or 1F5-S45A-SAv FPs labeled with 20-40 μCi (0.74-1.48 MBq) of 125I.
Twenty hours later, mice were injected with either 5.8 nmol of NAGB CA (50 μg) followed
4 hrs later by 1.2 nmol DOTA-biotin labeled with 20-40 μCi (0.74-1.48 MBq) of 111In or
with 5.8 nmol of BBTG CA (20 μg) followed 4 hrs later by 1.2 nmol of 111In -DOTA-bis-
biotin. Blood samples, tumors, and body organs were procured and 125I and 111In activities
measured in a dual channel gamma counter, adjusting for cross-over between channels (17).
Therapy studies
The therapeutic efficacy of 90Y using various pretargeted approaches was evaluated in
groups of 5 to 10 mice. Groups of mice with similar-sized, palpable tumors were selected
and randomized for the studies. Mice were given 2.8 nmol (400 μg) of 1F5-WT-SAv, 1F5-
Y43A-SAv, 1F5-S45A-SAv, or the negative control CC49-WT-SAv followed by 5.8 nmol
of either NAGB or BBTG CA 20 hrs later. A single dose of 1.2 nmol of either DOTA-biotin
or DOTA-bis-biotin labeled with 500 μCi (18.5 MBq) 90Y was administered 4 hrs after the
CA. Mice were assessed every few days for tumor volume measurements, weight change,
and general appearance. Mice were euthanized if xenografts exceeded 10% of total body
weight, caused obvious discomfort or impaired ambulation, or if mice lost more than 30% of
their baseline body weight.
Toxicity studies
Toxicity studies were performed in parallel cohort groups, corresponding to the therapy
groups. Mice were monitored for lethargy, poor grooming, weight loss and other behaviors
consistent with debility. Blood testing was performed 14 days after injection of 90Y, and at
the time of euthanasia. Laboratory tests performed included the leukocyte and platelet
counts, hemoglobin, aspartate aminotransferase (AST), alanine aminotransferase (ALT),
creatinine, and blood urea nitrogen (BUN) levels. Age-matched, untreated athymic mice
were used for comparisons of hematology and chemistry data.
RESULTS
Expression and purification of WT-SAv and mutant-SAv FPs
All FPs were successfully expressed in the periplasmic space of E. coli as soluble stable
tetramers with molecular weights of ~174 KDa (Fig. 1). Expression levels for the FPs
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varied, with the S45A-SAv construct producing the highest yield (358 mg/L), followed by
Y43A-SAv (144 mg/L) and WT-SAv (100 mg/L). (18) SDS-PAGE analysis confirmed
purities of ~95% for the WT-SAv and mutant-SAv FPs after iminobiotin chromatography.
All tetrameric FP bands resolved into a single species of MW ~ 44 kDa when the FPs were
denatured by boiling before electrophoresis, consistent with a single protein entity
dissociable into a homogeneous, monomeric subunit (Fig. 1).
In vitro characterizations of mutant-SAv FPs
Flow cytometry demonstrated similar binding of the WT-SAv, S45A-SAv, and Y43A-SAv
FPs and of the parental 1F5 antibody to CD20-expressing Ramos cells (Fig. 2). In vitro cell
binding assays were then performed to compare the capture and retention of radiolabeled
biotin moieties by FPs bound to CD20 on the surface of lymphoma cells (Fig. 3). As
expected, the engineered low-affinity mutant FPs, 1F5-S45A-SAv and 1F5-Y43A-SAv,
bound significantly less radiolabeled monovalent biotin (2.9 ± 0.003 % and 4.9 ± 0.010% of
the total 90Y activity presented to the cells, respectively) than did the WT-SAv FP (12.1 ±
0.02% of the 90Y activity added to the cultures). S45A-SAv and Y43A-SAv FPs were much
more successful, as designed, in binding and retaining radiolabeled divalent bis-biotin (18.1
± 0.005% and 17.4 ± 0.001% of applied 90Y activity, respectively). By comparison, WT-
SAv FP bound 25.6 ± 0.02 % of applied 90Y-labeled divalent bis-biotin. These results
demonstrate that the divalent binding of the bis-biotin ligand compensated for the lower
affinity of the Y43A and S45A mutant SAv molecules, yielding binding pairs at least
comparable to the standard WT-SAv and monovalent DOTA-biotin reagents.
Blood clearance studies
The blood clearances of 125I-labeled mutant-SA FPs were evaluated after administration of
CAs to athymic mice fed biotin-replete normal diets. Groups of 4 mice each were given 2.8
nmol of S45A-SAv or Y43A-SAv FP followed 20 hours later by divalent BBTG CA,
monovalent NAGB CA, or PBS (negative control). A single injection of 5.8 nmol BBTG
CA resulted in an ~ 80% decrease of circulating 125I-1F5-S45A-SAv within 30 minutes
(shown logarithmically in Fig. 4) and a ~60% decrease in 125I-1F5-Y43A-SAv (not shown).
In contrast, the monovalent biotin CA, NAGB, was ineffective at clearing the low
affinity 125I-1F5-S45A-SAv or 125I-1F5-Y43A-SAv FPs from the blood, with clearances not
significantly different from those seen in negative control mice treated with PBS (Fig. 4).
These results demonstrate that the bis-biotin BBTG CA we designed works effectively as
planned for the low affinity FPs, but that the standard NAGB CA, which possesses only a
single biotin moiety, is ineffective for these constructs.
Biodistribution studies
Biodistribution experiments were conducted in mice with 1F5-Y43A-SAv, 1F5-S45A-SAv,
and 1F5-WT-SAv FPs and biotin compounds using the “dual label” method described
previously. Groups of 5 athymic mice bearing Ramos xenografts were injected i.v. with 400
μg (2.8 nmol) of 125I-labeled WT-SAv, Y43A-SAv, or S45A-SAv FPs followed 20 hr later
by 5.8 nmol of BBTG or NAGB CA. Four hours later, mice were injected i.v. with 1.2 nmol
of 111In-DOTA-bis-biotin or 111In-DOTA-biotin. Mice were euthanized 24 hours (Fig. 5A)
or 48 hours (Fig. 5B) later and 125I and 111In were measured in excised tumors and normal
organs using a dual channel gamma counter, adjusting for cross-over of the two isotopes
between channels. Biodistributions using the mutant-SA FPs did not include groups of mice
on biotin-deficient diets since previous studies demonstrated no differences in tumor uptake
between mice on biotin-deficient diets and normal diets with mutant sAv conjugates (29).
There were no significant differences in tumor or normal organ biodistributions of 125I in
groups given mutant-SAv or WT-SAv FPs at either 24 or 48 hours, indicating that all the
anti-CD20 FPs have similar tumor targeting and tissue biodistributions (Fig. S1). Analyses
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of the biodistributions of 111In-labeled biotin compounds indicated that 111In-DOTA-bis-
biotin was effectively targeted to tumors in mice pretargeted with mutant-SAv FPs even
when mice were fed normal biotin-containing diets, whereas monovalent 111In- DOTA –
biotin was not effectively targeted to lymphoma xenografts with the standard WT-SAv FP
unless mice were fed rigorously restricted biotin-free diets (Fig. 5). Tumors from mice
pretargeted with Y43A-SAv FP followed by 111In-DOTA-bis-biotin contained 6.2 ± 1.7 %
of the injected 111In per gram of tumor (%ID/gm) after 24 h compared to 5.6 ± 2.2 %ID/g
with S45A-SAv but only 2.5 ± 1.6 %ID/g with WT-SAv FP (p = 0.01; Fig. 5A). The amount
of radioactivity in tumors of mice treated with the mutant FP/bis-biotin systems were similar
to the radioactivity in tumors excised from mice fed a biotin-deficient diet and treated with
the standard WT-SAv FP and DOTA-biotin PRIT system (7.2 ± 3.2 %ID/g after 24 h,
p>0.3) . Similar conclusions were derived from biodistribution studies conducted 48 hours
after injection of 111In-labeled biotin compounds (Fig. 5B). Tumors excised from mice on
normal diets treated with the mutant-SAv FPs followed by 111In-DOTA-bis-biotin contained
4.6 ± 1.0 %ID/g of the injected 111In- DOTA-bis-biotin with Y43A-SAv FP and 3.6 ± 1.1
%ID/g with S45A-SAv FP after 48 hours compared to 1.1 ± 0.3 %ID/g with WT-SAv FP
(Fig. 6B; p < 0.0001). Tumors from mice fed a biotin-deficient diet and treated with WT-
SAv FP and monovalent 111In-DOTA-biotin contained 5.2 ± 0.4 %ID/g after 48 hours. The
biodistributions of 111In- DOTA-bis-biotin and 111In-DOTA-biotin in normal organs were
similar in mice treated with either mutant-SAv FPs or WT-SAv FP, except that radioactivity
in the blood and liver were slightly higher with mutant-SAv FPs, especially for Y43A-SAv
(Fig. 5). The amount of radioactivity measured in tumors of mice fed normal diets treated
with WT-SAv FP did not vary significantly whether 111In-DOTA-biotin or 111In-DOTA-
bis-biotin was used, indicating that even the bis-biotin ligand was not able to displace pre-
bound endogenous biotin from the biotin-binding sites of WT-SAv. Overall, the
combination of mutant-SAv FPs, BBTG CA, and DOTA-bis-biotin resulted in superior
biodistributions of radioactivity compared with conventional WT-SAvFP, NAGB CA, and
DOTA-biotin in mice fed normal diets, where endogenous biotin levels are known to be
high.
Therapy and toxicity studies
Therapy studies compared the efficacy of 90Y-labeled biotin compounds for treating
lymphoma xenografts in mice pretargeted with the WT and mutant SAv FPs or with a non-
binding negative control, CC49-WT-SAv FP (Fig. 6). Mice were assigned into 6 different
groups and fed either a biotin-deficient diet or a regular biotin-containing diet. The median
tumor size was 86 ± 42 mm3 at the initiation of the study with no significant differences
between groups. Mice were treated with WT-SAv, S45A-SAv, Y43A-SAv, or CC49-WT-
SAv FPs followed 20 hours later by either NAGB or BBTG CA. A single injection of 500
μCi [90Y]-labeled DOTA-bis-biotin or monovalent DOTA-biotin was given 4 hours after the
CA injection. Animals on a regular diet that received Y43A-SAv and S45A-SAv FPs had
mean tumor volumes of 236 ± 66 mm3 and 543 ± 320 mm3 11 days after therapy,
respectively, compared to 1435 ± 212 mm3 for mice that received a non-binding control
CC49-SAv FP (p < 0.0001) and 1129 ± 322 mm3 for animals that received WT-SAv FP (p <
0.03). Administration of WT-SAv FP to mice fed a biotin-deficient diet was associated with
the most significant delay in tumor growth (11 ± 22 mm3 at day 11). Treatment was well
tolerated with no evidence of acute toxicity. Complete blood counts, creatinine, and
transaminase levels 14 days after therapy were similar in all groups of mice except that
mildly lower leukocyte counts were observed in mice in all of the treatment groups
compared to control, untreated mice (Supplementary Table II).
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DISCUSSION
The efficacy of RIT in patients with NHL has been established by a multitude of clinical
trials, but the majority of patients treated with non-myeloablative doses of RIT eventually
relapse (37-38). PRIT using SAv-biotin methodology has emerged as one promising
approach to deliver potentially curative radiation doses to tumors while minimizing
toxicities arising from the nonspecific radiation delivered to normal organs. While the high
affinity of SAv for biotin is essential for this pretargeting system, this tight interaction can
paradoxically present a significant limitation when naturally occurring endogenous biotin
irreversibly blocks the SAv binding sites, decreases the capacity of SAv to bind radiolabeled
DOTA-biotin, and reduces therapeutic efficacy. Although short-term biotin-depletion can be
routinely achieved in mouse models, rigorous biotin-depletion is difficult in clinical settings
due to its ubiquitous presence in all common foods. Even if endogenous biotin is
successfully depleted, suboptimal targeting may still occur since the extremely slow “off
rate” of radiobiotin hinders its diffusion to the center of tumor masses, due to “trapping” of
radiobiotin in perivascular or peripheral locations by irreversible, high-affinity binding to
the most accessible tumor cells. Computer models and experimental data have verified that
such a “binding-site barrier” does exist and may compromise therapeutic efficacy of
radioimmunoconjugates of extremely high binding affinities, though this problem can be at
least partially overcome by administration of a large excess of Ab-SAv conjugate and
radiobiotin (39-40). In this study, we demonstrate the potential advantage of a novel,
engineered PRIT system utilizing mutant-SAv FPs and bivalent radiolabeled DOTA-bis-
biotin for treatment of lymphomas in situations where endogenous biotin may limit the
effectiveness of standard SAv-biotin PRIT. Our group has previously shown that specific
delivery of high doses of radiation to tumor sites is achievable even in the presence of
endogenous biotin using chemical conjugates of 1F5 Ab and mutant-SAv protein produced
using heterobifunctional cross-linkers in combination with bivalent biotin ligands (28-29).
Here we describe the genetic engineering, expression, in vitro characterization, and in vivo
testing of novel 1F5-mutant-SAv FPs, which are more homogeneous, more amenable to
scale-up, and less costly to manufacture than the previously described Ab-mutant-SAv
chemical conjugates (33).
We have produced anti-CD20 mutant-SAv FPs that maintain the full antigen-binding
capacity of the parent monoclonal Ab, but have a reduced avidity for endogenous biotin
compared to WT-SAv FP. We selected the Y43A and S45A mutants for incorporation into
scFv4SAv FPs from a panel of available mutants produced by site-directed mutagenesis
based on prior in vitro assays, which suggested that these particular mutations would be
most advantageous (27, 29). The Y43A-SAv and S45A-SAv mutant molecules have 67 and
907-fold lower affinity for biotin, respectively, compared to WT-SAv, but retain robust
binding to divalent biotin compounds, as demonstrated by their significantly slower off-rates
for bis-biotin than biotin (27). Mutant-SAv FPs were directly compared with WT-SAv FP
using a cell binding assay (Fig. 3), which demonstrated that both Y43A-SAv and S45A-SAv
FPs have significantly lower affinity for monovalent biotin compared to WT-SAv FP, but
have sufficiently high affinity to efficiently capture bis-biotin ligands. These in vitro results
suggest that the lower affinity of the mutant-SAv FPs for monovalent biotin may allow pre-
bound endogenous monovalent biotin to quickly dissociate, yet permit the durable capture
and retention of radiolabeled divalent bis-biotin ligands by mutant-SAv FPs. To utilize this
mutant-SAv FP and bis-biotin system effectively, a synthetic trigalactose-containing bis-
biotin CA was conceptualized and generated by our group to facilitate blood clearance of the
mutant-SAv FPs (28). Pharmacokinetic experiments showed that treatment of mice with
BBTG CA resulted in efficient clearance of mutant-SAv FPs from the blood. As expected,
the standard CA containing a single biotin moiety (NAGB) had a negligible effect on the
blood clearance of the mutant-SAv FPs.
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Biodistribution experiments confirmed that the uptake and retention of radiolabeled DOTA-
biotin by WT-SAv FP was significantly compromised at tumor sites when animals were fed
a regular diet, presumably because of the deleterious impact of endogenous biotin blocking
the biotin-binding sites of SAv. In marked contrast, the mutant-SAv FPs exhibited excellent
tumor retention of radiolabeled DOTA-bis-biotin even in animals fed a regular biotin-rich
diet. The amounts of radioactivity in normal tissues were similar in mice treated with
mutant-SAv and WT-SAv FPs, except for the blood and liver, which contained slightly more
radioactivity in groups treated with mutant-SAv than in mice treated with WT-SAv and
NAGB CA. We presume these differences emerged because the BBTG CA was less
efficient at clearing mutant-SAv FPs from the blood than the NAGB CA was at clearing
WT-SAv.(17, 41) Therefore, further optimization of the bisbiotin CA is planned using
variations in the galactose content of the molecule.
In therapy experiments, mutant-SAv FPs in combination with 90Y-DOTA-bis-biotin
produced significant tumor growth delays in mice bearing lymphoma xenografts fed biotin-
replete normal diets while the standard regimen, utilizing WT-SAv and 90Y-DOTA-biotin,
had no significant effect on tumor growth in the presence of endogenous biotin. These data
support the hypothesis that mutant-SAv FPs with optimized biotin-binding affinities can
improve the amount of radiation delivered specifically to tumor sites compared to WT-SAv
FP in the presence of competing endogenous biotin.
Although it must be acknowledged that the current gold standard combination of WT-SA FP
and radiolabeled DOTA-biotin remains superior in situations where rigorous biotin
depletion can be achieved, these studies demonstrate the promise of such a genetically
engineered PRIT system for situations where endogenous biotin may limit its efficacy
through competitive inhibition at the SAv binding site. In addition, it is conceivable that the
SAv mutants used in these experiments may not possess the optimal off-rates for biotin and
bis-biotin to maximize tumor retention. Therefore, additional mutant-SAv FPs will be
engineered and tested to further optimize the affinity and off-rate for monovalent biotin and
bivalent biotin ligands.
We acknowledge that one potential limitation of SAv-biotin pretargeting systems is the
immunogenicity of SAv (and of murine Ab). Although human anti-mouse Ab (HAMA) and
human anti-SAv Ab (HASA) may be major limitations for applications in
immunocompetent patients and for experimental regimens requiring repetitive rounds of
therapy, we do not anticipate that immunogenicity will be a major limitation for this
approach in patients with advanced leukemia and lymphoma, who are the focus of our
investigations. We have administered RIT using murine Ab to 476 patients with non-
Hodgkin lymphoma or acute myeloid leukemia at our center since 1987. Only 14 of these
476 patients (2.9%) formed HAMA between the dosimetric and therapeutic infusions of
radiolabeled Ab. Furthermore, we recently opened a clinical trial of PRIT using a murine
anti-CD45 Ab with SAv and radiolabeled biotin for patients with acute myeloid leukemia
(ClinicalTrials.gov identifier NCT00988715; IND # 104683). No immune responses to
either Ab or SAv have yet been detected in the 5 patients treated, presumably due to the
compromised immune system of these patients (unpublished data). HASA have also not
been major impediments in published studies of lymphoma patients treated with
streptavidin-biotin PRIT by others.(19, 22) We believe that our ongoing trial, and previous
PRIT studies by others, demonstrate that Ab-SA PRIT approaches are translatable to the
clinic.
In summary, we have demonstrated the potential of rationally engineered mutant-SAv FPs to
be used in conjunction with divalent bis-biotin CA and bis-biotin radioisotope carriers to
circumvent the potential blocking effects of endogenous biotin. This approach may allow the
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effective delivery of higher doses of radiation to tumor sites than is possible with standard
SAv-biotin PRIT systems in settings where rigorous biotin depletion is not feasible.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Conventional radioimmunotherapy (RIT) induces long-term durable remissions in over
50% patients with relapsed or refractory indolent non-Hodgkin’s lymphoma (NHL). Our
research goal is to optimize RIT using a multistep pretargeted RIT scheme (PRIT)
employing genetically engineered mutant-streptavidin fusion proteins and bis-biotin
reagents that provide an attractive alternative to current methods. This molecular
engineering approach is particularly attractive in clinical settings where high endogenous
biotin levels prevail due to dietary intake of this vitamin, leading to diminished efficacy
of standard streptavidin/biotin reagents.
We anticipate that this approach will result in superior efficacy compared to both
conventional RIT and current PRIT approaches. If the results are promising, we
anticipate eventually translating this approach into phase I/II clinical studies of PRIT for
patients with relapsed B cell lymphomas.
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Fig 1.
Schematization of the IF5 scFvSAv gene and its derivative tetravalent FP. A) The scFvSAv
fusion gene is comprised of the scFv gene of the murine IgG1 anti-CD20 1F5 Ab fused to
the full length SAv gene; B) a diagrammatic representation of the tetravalent FP that
spontaneously forms after secretion into the periplasmic space of E. coli; C) Representative
HPLC tracing of a purified FP (S45A-SA); SDS-PAGE analyses of unpurified and
iminobiotin-purified 1F5(scFv)4SAv WT FP (D), Y43A-SAv FP (E), and S45A-SAv FP (F),
respectively. The mass of the intact FPs (174 kDa) and the monomers (44 kDa) are indicated
on each SDS-PAGE gels (4-12% Tris-glycine; (Invitrogen, Carlsbad, CA) stained with
Coomassie blue. Lane M, migration of pre-stained molecular weight standards (SeeBlue
plus; Invitrogen, Carlsbad, CA). Lane 1, loaded E. coli crude lysate, containing
1F5(scFv)4SAv WT FP. Lanes 2 and 3, flow-through and wash fractions, respectively, from
an iminobiotin purification column. Lanes 4 and 5, iminobiotin-purified FP without boiling
(lane 4) or denatured by boiling for 5 minutes to resolve the tetramers into monomers (lane
5).
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Fig 2.
Flow cytometry showing equivalent binding of the 1F5-WT-SAv, 1F5-Y43A-SAv, and 1F5-
S45A-SAv FPs to the surface of CD20-expressing Ramos cells (Fig. 2B). For comparison,
binding of a non-binding negative control FP, CC49-WT-SAv (Fig 2B), a non-binding,
isotype matched, negative control Ab, HB8181 (Fig. 2A) and of the parental 1F5 anti-CD20
Ab (positive control, Fig. 2A) are also shown.
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Fig 3.
Cell binding assay comparing the binding of 90Y-DOTA-biotin and 90Y-DOTA-bisbiotin to
Ramos cells previously saturated with 1F5-WT-SAv FP, 1F5-Y43A-SAv FP, 1F5-S45A-
SAv FP, or CC49-SA FP (negative control) or to untreated cells incubated with PBS. Ramos
cells (1.0 × 106 per sample) were incubated with 25 μl of 20ug/ml 1F5-Y43A-SAv, 1F5-
S45A-SAv, 1F5-WT-SAv, or CC49-WT-SAv FPs in a 96 round bottom ELISA plate at 4 °C
for 60 minutes. Cells were then washed twice in PBS. Next, 100 ng/ml of 90Y-DOTA–
biotin or 90Y-DOTA–bis-biotin were added to the cells and incubated at 4°C for 60 minutes.
Cells were washed twice with PBS and then bound radioactivity was measured in a gamma
counter.
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Fig 4.
Blood Clearance of 125I-1F5-S45A-SA FP using either a monovalent biotin CA
(NAGB,◆) or a synthetic bis-biotin CA (BBTG-CA,▴). CAs (5.8 nmol) were injected 20
hours after administration of FP, then mice were bled serially and blood radioactivity
measured in a gamma counter. Control mice received 2.8 nmol of FPs without any CA (●).
Results are expressed as the percent of the injected dose of radioactivity present per gram of
blood (%ID/g) on a logarithmic scale.
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Fig 5.
Biodistributions of 111In-labeled biotin compounds in tumors and normal organs of athymic
mice bearing Ramos xenografts pretargeted with 1F5-S45A-SAv, 1F5-Y43ASAv, or 1F5-
WT-SAv FP. Mice were fed either normal or biotin-deficient diets for 5-6 days before
injection of 2.8 nmol of FPs, as indicated. Twenty-four hours later 5.8 nmol of either
monovalent NAGB CA or divalent bis-biotin CA was injected. After another 4 hours, mice
were injected with 1.2 nmol of 111In-labeled DOTA-biotin or 111In-labeled bisbiotin.
Results are shown for mice sacrificed either 24 hours (A) or 48 hours (B) after
administration of the radiolabeled biotin ligands.
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Fig 6.
Growth of Ramos xenografts in athymic mice pretargeted with CC49-SAv FP (nonbinding
negative control, ●), 1F5-S45A-SAv FP (▴), 1F5-Y43A-SA FP (∎), 1F5-WT-SAv (◆) or
1F5-WT-SAv with a biotin deficient diet (⦿) followed by the indicated CA and 90Y-
DOTA-bisbiotin or 90Y-DOTA-biotin. Mice were fed a normal, biotin-replete diet unless
otherwise specified.
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